clinical trial · NCT07413250
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
Alexion Pharmaceuticals, Inc.·—·active not recruiting·n = 50
Paroxysmal Nocturnal HemoglobinuriaPNHDanicopanSoliris/Ultomiris
brief summary
This is a noninterventional registry-based cohort study utilizing data collected on danicopan-treated patients with paroxysmal nocturnal hemoglobinuria (PNH) through the International PNH Interest Group (IPIG) PNH registry. The primary objectives seek to characterize the long-term safety profile of danicopan as add-on therapy to ravulizumab/eculizumab in participants with PNH.
started
Jan 14, 2026
primary completion
Jan 15, 2030
completion
Jan 15, 2030
last updated
Feb 17, 2026
official title
A Study to Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of International PNH Interest Group (IPIG)-Registry Data
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol